Niagen Bioscience (FRA:OCD1) Cyclically Adjusted PS Ratio: (As of Sep. 20, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OCD1 Niagen Bioscience Inc FRA:OCD1
68 GF Score
Price €2.60
GF Value €3.77
! 2 Warning Signs
View Full Analysis

What is Niagen Bioscience Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Niagen Bioscience  (FRA:OCD1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Niagen Bioscience Cyclically Adjusted PS Ratio Related Terms


Niagen Bioscience Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Niagen Bioscience's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Niagen Bioscience Cyclically Adjusted PS Ratio Chart

Niagen Bioscience Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.57 2.19 1.70 5.95 5.60

Niagen Bioscience Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.85 8.55 5.52 3.51 2.62

FRA:OCD1 vs CAMP, ALEC, ELDN: Cyclically Adjusted PS Ratio Comparison

For the Packaged Foods subindustry, Niagen Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Niagen Bioscience Cyclically Adjusted PS Ratio vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Niagen Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Niagen Bioscience's Cyclically Adjusted PS Ratio falls into.


FRA:OCD1
68GF Score
Niagen Bioscience Inc FRA:OCD1
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Niagen Bioscience Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Niagen Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Niagen Bioscience's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.31/333.9520*333.9520
=0.310

Current CPI (Jun. 2026) = 333.9520.

Niagen Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.093 241.428 0.129
201612 0.110 241.432 0.152
201703 0.083 243.801 0.114
201706 0.091 244.955 0.124
201709 0.110 246.819 0.149
201712 0.125 246.524 0.169
201803 0.097 249.554 0.130
201806 0.119 251.989 0.158
201809 0.127 252.439 0.168
201812 0.144 251.233 0.191
201903 0.160 254.202 0.210
201906 0.178 256.143 0.232
201909 0.188 256.759 0.245
201912 0.198 256.974 0.257
202003 0.218 258.115 0.282
202006 0.228 257.797 0.295
202009 0.197 260.280 0.253
202012 0.209 260.474 0.268
202103 0.190 264.877 0.240
202106 0.216 271.696 0.265
202109 0.215 274.310 0.262
202112 0.227 278.802 0.272
202203 0.225 287.504 0.261
202206 0.230 296.311 0.259
202209 0.248 296.808 0.279
202212 0.279 296.797 0.314
202303 0.281 301.836 0.311
202306 0.249 305.109 0.273
202309 0.239 307.789 0.259
202312 0.263 306.746 0.286
202403 0.271 312.332 0.290
202406 0.280 314.175 0.298
202409 0.299 315.301 0.317
202412 0.334 315.605 0.353
202503 0.348 319.799 0.363
202506 0.318 322.561 0.329
202509 0.336 324.800 0.345
202512 0.344 324.054 0.355
202603 0.318 330.213 0.322
202606 0.310 333.952 0.310

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?

Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued. The current stock price of €2.60 is trading 31% below its estimated GF Value™ of €3.77.

Key valuation signals for FRA:OCD1:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €3.77 vs. price of €2.60 (31% below fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Niagen Bioscience Business Description

Other Exchanges NAGE:USAOCD1:Germany
Address 10900 Wilshire Boulevard, Suite 600, Los Angeles, CA, USA, 90024
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
68GF Score

Get the complete analysis for FRA:OCD1

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.60
Price
€3.77
GF Value